Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

Details

Request a copyRequest a copy
Serval ID
serval:BIB_996A49F24542
Type
Article: article from journal or magazin.
Publication sub-type
Editorial
Collection
Publications
Institution
UNIL/CHUV
Title
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
Journal
Annals of oncology
Author(s)
Peters S., Dafni U., Boyer M., De Ruysscher D., Faivre-Finn C., Felip E., Garrido P., Girard N., Guckenberger M., Haanen J., Le Pechoux C., Mornex F., Ozsahin M., Paz-Ares L., Planchard D., Raben D., Ramalingam S., Reck M., Smit E., Stahel R., Stenzinger A., Swanton C., Vallone S., Garassino M.C.
ISSN
1569-8041 (Electronic)
ISSN-L
0923-7534
Publication state
Published
Issued date
01/02/2019
Peer-reviewed
Oui
Volume
30
Number
2
Pages
161-165
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
OAI-PMH
oai:serval.unil.ch:BIB_996A49F24542
DOI
10.1093/annonc/mdy553
Pubmed
30624547
Web of science
000463940300003
Create date
22/01/2019 17:42
Last modification date
20/08/2019 16:00
Usage data